ALX Oncology Holdings Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDALX Oncology Holdings Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 60), indicating performance broadly in line with the market. Earnings growth of 29% provides fundamental context to the price action. Investors should exercise caution due to high volatility (118% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.72 | +21.84% | ABOVE |
| 50 SMA | $1.94 | +7.84% | ABOVE |
| 100 SMA | $1.79 | +16.48% | ABOVE |
| 150 SMA | $1.71 | +21.96% | ABOVE |
| 200 SMA | $1.53 | +36.65% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ALXO in an uptrend right now?
ALXO has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ALXO is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ALXO overbought or oversold?
ALXO's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is ALXO outperforming the market?
ALXO has a Relative Strength (RS) Rating of 60 out of 99. ALXO is performing about average compared to the market.
Where is ALXO in its 52-week range?
ALXO is trading at $2.09, which is 79% of its 52-week high ($2.66) and 75% above its 52-week low ($0.40).
How volatile is ALXO?
ALXO has a Beta of 1.44 and 52-week volatility of 118%. It's more volatile than the S&P 500 - expect bigger swings.